The latest updated of drug registration lists on 03 May 2025.

Close

No Brand Name Ingredients Dosage Form Primary Packaging Indications EDL License Owner Manufacturer Country Activity Reg No. Reg Date Expiry Date Action
651 NEUROMET TABLETS MECOBALAMIN JP 500 MCG TABLETS ALU-ALU BLISTER • Peripheral neuropathy (e.g. diabetic, alcoholic and uremic neuropathy) • Drug induced neuropathy • Neurological disease & aging • Symptoms of Vitamin B12 deficiency. • Prolonged inadequate or incorrect nutrition (e.g. strict vegetarian diet) • Malabsorption due to insufficient production of intrinsic factor • Hyperchromic or Macrocytic or Megaloblastic anemia, Pernicious anemia, Biermer anemia, Addison’s anemia • Congenital disorders of Vitamin B12 transport Yes EXAMED CO.,LTD MARTIN DOW MARKER LTD PAKISTAN CERTIFICATE RELEASED 01 I 5851/25 2025-01-23 2030-01-22 View
652 PRELIN 50 MG CAPSULES PREGABALIN USP 50 MG CAPSULE ALU-ALU BLISTER Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for adult patients with partial onset seizures • Management of fibromyalgia • Management of neuropathic pain associated with spinal cord injury Yes EXAMED CO.,LTD MARTIN DOW LTD PAKISTAN CERTIFICATE RELEASED 01 I 5852/25 2025-01-23 2030-01-22 View
653 PRELIN 75 MG CAPSULES PREGABALIN USP 75 MG CAPSULE ALU-ALU BLISTER Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for adult patients with partial onset seizures • Management of fibromyalgia • Management of neuropathic pain associated with spinal cord injury Yes EXAMED CO.,LTD MARTIN DOW LTD PAKISTAN CERTIFICATE RELEASED 01 I 5853/25 2025-01-23 2030-01-22 View
654 ROSWIN 10 MG TABLETS ROSUVASTATIN CALCIUM USP EQ.TO ROSUVASTATIN 10 MG FILM COATED TABLET ALU-ALU BLISTER • adjunctive therapy to diet to reduce elevated total cholesterol (total C), LDL, apolipoprotein B (ApoB), non-HDL, and TG levels and to increase HDL in adults with primary hyperlipidemia or mixed dyslipidemia. • adjunct to reduce total C, LDL and ApoB levels in adolescents. • Who are at least 1 year after menarchy (women), 10 to 17 years with heterozygous familial hypercholesterolemia (HeFH) and in those who, after dietary treatment, have an LDL >190mg/dl or. • >160mg/dl and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors. • For the treatment of hypertriglyceridemia in adults. • For the treatment of primary dysbetalipoproteinemia (type III hyperlipoproteinemia). •Adjunct therapy to other lipid-lowering treatments (e.g., LDL Apheresis) or alone if such treatments are not available to reduce LDL, total C, and ApoB in adults with hypercholesterolemia homozygous familial (HoFH). • Adjunct to slow the progression of atherosclerosis in adults as • Part of a treatment strategy aimed at lowering total C and LDL to target levels. • Reduces the risk of myocardial infarction, stroke and artery Revascularization procedures in people at increased risk of cardiovascular disease. Yes EXAMED CO.,LTD MARTIN DOW LTD PAKISTAN CERTIFICATE RELEASED 01 I 5854/25 2025-01-23 2030-01-22 View
655 ROSWIN 20 MG TABLETS ROSUVASTATIN CALCIUM USP EQ.TO ROSUVASTATIN 20 MG FILM COATED TABLET ALU-ALU BLISTER • adjunctive therapy to diet to reduce elevated total cholesterol (total C), LDL, apolipoprotein B (ApoB), non-HDL, and TG levels and to increase HDL in adults with primary hyperlipidemia or mixed dyslipidemia. • adjunctto reduce total C, LDL and ApoB levels in adolescents. • Who are at least 1 year after menarchy (women), 10 to 17 years with heterozygous familial hypercholesterolemia (HeFH) and in those who, after dietary treatment, have an LDL >190mg/dl or. • >160mg/dl and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors. • For the treatment of hypertriglyceridemia in adults. • For the treatment of primary dysbetalipoproteinemia (type III hyperlipoproteinemia). •Adjunct therapy to other lipid-lowering treatments (e.g., LDL Apheresis) or alone if such treatments are not available to reduce LDL, total C, and ApoB in adults with hypercholesterolemia homozygous familial (HoFH). • Adjunct to slow the progression of atherosclerosis in adults as • Part of a treatment strategy aimed at lowering total C and LDL to target levels. • Reduces the risk of myocardial infarction, stroke and artery Revascularization procedures in people at increased risk of cardiovascular disease. Yes EXAMED CO.,LTD MARTIN DOW LTD PAKISTAN CERTIFICATE RELEASED 01 I 5855/25 2025-01-23 2030-01-22 View
656 ROSWIN 5 MG TABLETS ROSUVASTATIN CALCIUM USP EQ.TO ROSUVASTATIN 5 MG FILM COATED TABLET ALU-ALU BLISTER • adjunctive therapy to diet to reduce elevated total cholesterol (total C), LDL, apolipoprotein B (ApoB), non-HDL, and TG levels and to increase HDL in adults with primary hyperlipidemia or mixed dyslipidemia. • adjunctto reduce total C, LDL and ApoB levels in adolescents. • Who are at least 1 year after menarchy (women), 10 to 17 years with heterozygous familial hypercholesterolemia (HeFH) and in those who, after dietary treatment, have an LDL >190mg/dl or. • >160mg/dl and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors. • For the treatment of hypertriglyceridemia in adults. • For the treatment of primary dysbetalipoproteinemia (type III hyperlipoproteinemia). •Adjunct therapy to other lipid-lowering treatments (e.g., LDL Apheresis) or alone if such treatments are not available to reduce LDL, total C, and ApoB in adults with hypercholesterolemia homozygous familial (HoFH). • Adjunct to slow the progression of atherosclerosis in adults as • Part of a treatment strategy aimed at lowering total C and LDL to target levels. • Reduces the risk of myocardial infarction, stroke and artery Revascularization procedures in people at increased risk of cardiovascular disease. Yes EXAMED CO.,LTD MARTIN DOW LTD PAKISTAN CERTIFICATE RELEASED 01 I 5856/25 2025-01-23 2030-01-22 View
657 XANILO 30 MG DDR CAPSULE DEXLANSOPRAZOLE DUAL DELAYED RELEASE PELLETS EQ.TO DEXLANSOPRAZOLE 30 MG CAPSULE ALU-ALU BLISTER • Healing of Erosive Esophagitis Xanilo is indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. •Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Xanilo is indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. • Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Xanilois indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks. No EXAMED CO.,LTD MARTIN DOW LTD PAKISTAN CERTIFICATE RELEASED 01 I 5857/25 2025-01-23 2030-01-22 View
658 XANILO 60 MG DDR CAPSULE DEXLANSOPRAZOLE DUAL DELAYED RELEASE PELLETS EQ.TO DEXLANSOPRAZOLE 60 MG CAPSULE ALU-ALU BLISTER • Healing of Erosive Esophagitis Xanilo is indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. •Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Xanilo is indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. • Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Xanilois indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks. No EXAMED CO.,LTD MARTIN DOW LTD PAKISTAN CERTIFICATE RELEASED 01 I 5858/25 2025-01-23 2030-01-22 View
659 ALLRECOV NALTREXONE HYDROCHLORIDE 150 MG IMPLANT VIAL for the prevention of relapse following opioid detoxification in patients with opioid dependence. No MUNGMISAI PHARMACEUTICAL SOLE CO.,LTD SHENZHEN SCIENCARE PHARMACEUTICAL CO., LTD CHINA CERTIFICATE RELEASED 01 I 5859/25 2025-03-07 2030-03-06 View
660 ALRIN TABLET 180 MG FEXOFENADINE HYDROCHLORIDE 180 MG FILM COATED TABLET ALU-ALU BLISTER IN ADULT AND CHILDREN 12 YEARS AND OLDER FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS No EXAMED CO.,LTD CCL PHARMACEUTICALS (PVT.) LTD. PAKISTAN CERTIFICATE RELEASED 08 I 5588/23 2023-09-05 2026-09-04 View
 
© 2014 ສະຫງວນລິຂະສິດໂດຍ ກົມອາຫານ ແລະ ຢາ, ກະຊວງສາທາລະນະສຸກ, ສປປລາວ.
ຕິດຕໍ່ ກອຢ      ອີເມວ      ເຂົ້າລະບົບ